Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 8/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333290 | 1.00 | CA1 (0.50) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL7765532 | 0.86 | CA1 (0.46) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL20254237 | 0.84 | CA1 (0.47) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL20254210 | 0.84 | CA1 (0.47) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL23607312 | 0.81 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL1563568 | 0.81 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL148100 | 0.81 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL148099 | 0.81 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL23849248 | 0.81 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL1369240 | 0.81 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084154-B1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | BAYER IP GMBH (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20100292230-A1 | Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292230-A1 | Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| WO-2009007026-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008022786-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273789-A1 | AMINOACYL PRODRUGS | AADAC, DNPEP, AADAT | CA1 3266/4885CA2 2133/4885CA7 2808/4885 |
| US-20100292230-A1 | Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders | AADAC, AADAT, DNPEP | CA1 3231/4885CA2 2181/4885CA7 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.